This announcement is a separate document:
AstraZeneca | 6-K: Astrazeneca Plc Announced That, On 5 March 2024, An Award of the Company's Ordinary Shares of $0.25 Each Vested to Pascal Soriot, Executive Director and Chief Executive Officer, Under the Terms of the Astrazeneca Deferred Bonus Plan
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.